{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T02:22:52Z","timestamp":1700274172434},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1007\/bf02982803","type":"journal-article","created":{"date-parts":[[2008,11,5]],"date-time":"2008-11-05T12:13:48Z","timestamp":1225887228000},"page":"385-393","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Monoclonal Antibody Therapy for B-Cell Lymphoma"],"prefix":"10.1007","volume":"76","author":[{"given":"Antonio J.","family":"Grillo-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,12,1]]},"reference":[{"key":"BF02982803_CR1","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1200\/JCO.1994.12.7.1497","volume":"12","author":"RO Dillman","year":"1994","unstructured":"Dillman RO. Antibodies as cytotoxic therapy.J Clin Oncol. 1994; 12:1497\u20131515.","journal-title":"J Clin Oncol."},{"key":"BF02982803_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler G, Milstein C. Continuous cultures of fused secreting antibody of redefined specificity.Nature. 1975;256:495\u2013497.","journal-title":"Nature"},{"issue":"suppl 14","key":"BF02982803_CR3","first-page":"66","volume":"26","author":"AJ Grillo-L\u00f3pez","year":"1999","unstructured":"Grillo-L\u00f3pez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.Semin Oncol. 1999;26(suppl 14):66\u201373.","journal-title":"Semin Oncol."},{"key":"BF02982803_CR4","first-page":"700","volume":"2","author":"AJ Grillo-L\u00f3pez","year":"2001","unstructured":"Grillo-L\u00f3pez AJ. The important role of monoclonal antibodies in the treatment of non-Hodgkin\u2019s lymphomas.Oncol Spectr. 2001;2: 700\u2013705.","journal-title":"Oncol Spectr."},{"key":"BF02982803_CR5","first-page":"48","volume-title":"WHO Handbook for Reporting Results of Cancer Treatment","author":"World Health Organization","year":"1979","unstructured":"World Health Organization.WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979:48."},{"key":"BF02982803_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"M Oken","year":"1982","unstructured":"Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol. 1982;5:649\u2013655.","journal-title":"Am J Clin Oncol."},{"key":"BF02982803_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJM198203043060906","volume":"306","author":"R Miller","year":"1982","unstructured":"Miller R, Maloney D, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.N Engl J Med. 1982;306:517\u2013522.","journal-title":"N Engl J Med."},{"key":"BF02982803_CR8","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1200\/JCO.1990.8.5.792","volume":"8","author":"D Scheinberg","year":"1990","unstructured":"Scheinberg D, Straus D, Yeh S, et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin\u2019s lymphoma: effects of tumor burden and antigen expression.J Clin Oncol. 1990;8:792\u2013803.","journal-title":"J Clin Oncol."},{"key":"BF02982803_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/BF01741331","volume":"32","author":"A Hekman","year":"1991","unstructured":"Hekman A, Honselaar A, Vuist WMJ, et al. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody.Cancer Immunol Immunother. 1991;32:364\u2013372.","journal-title":"Cancer Immunol Immunother"},{"key":"BF02982803_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","volume":"69","author":"O,Appelbaum F Press","year":"1987","unstructured":"Press O,Appelbaum F, Ledbetter J, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas.Blood. 1987; 69:584\u2013591.","journal-title":"Blood"},{"key":"BF02982803_CR11","first-page":"843","volume":"98","author":"TA Davis","year":"2001","unstructured":"Davis TA, Kaminski MS, Leonard JP, et al. Results of a randomized trial of Bexxar (tositumomab and iodine I 131 tositumomab) vs unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin\u2019s lymphoma [abstract].Blood. 2001;98:843a. Abstract 3503.","journal-title":"Blood"},{"key":"BF02982803_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-L\u00f3pez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma.Ann Oncol. 1998;9:995\u20131001.","journal-title":"Ann Oncol."},{"key":"BF02982803_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LD Piro","year":"1999","unstructured":"Piro LD, White CA, Grillo-L\u00f3pez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma.Ann Oncol. 1999;10:655\u2013661.","journal-title":"Ann Oncol."},{"issue":"suppl 12","key":"BF02982803_CR14","first-page":"9","volume":"27","author":"AJ Grillo-L\u00f3pez","year":"2000","unstructured":"Grillo-L\u00f3pez AJ. Rituximab: an insider\u2019s historical perspective.Semin Oncol. 2000;27(suppl 12):9\u201316.","journal-title":"Semin Oncol."},{"key":"BF02982803_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1042\/bst0250705","volume":"25","author":"DR Anderson","year":"1997","unstructured":"Anderson DR, Grillo-L\u00f3pez A, Varns C, et al. Targeting cytotoxic immunotherapy: targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin\u2019s B-cell lymphoma.Biochem Soc Trans. 1997;25: 705\u2013708.","journal-title":"Biochem Soc Trans."},{"key":"BF02982803_CR16","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994;84:2457\u20132466.","journal-title":"Blood"},{"key":"BF02982803_CR17","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, et al. IDEC-C2B8 (rit-uximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma.Blood. 1997;90: 2188\u20132195.","journal-title":"Blood"},{"key":"BF02982803_CR18","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"B Cheson","year":"1999","unstructured":"Cheson B, Horning S, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphoma.J Clin Oncol. 1999;17:1244\u20131253.","journal-title":"J Clin Oncol."},{"key":"BF02982803_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1023\/A:1008332713631","volume":"11","author":"AJ Grillo-L\u00f3pez","year":"2000","unstructured":"Grillo-L\u00f3pez AJ, Cheson BD, Horning SJ, et al. Response criteria for NHL: importance of \u201cnormal\u201d lymph node size and correlations with response rates.Ann Oncol. 2000;11:399\u2013408.","journal-title":"Ann Oncol."},{"key":"BF02982803_CR20","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, et al. Chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825\u20132833.","journal-title":"J Clin Oncol."},{"key":"BF02982803_CR21","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","volume":"17","author":"TA Davis","year":"1999","unstructured":"Davis TA, White CA, Grillo-L\u00f3pez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin\u2019s lymphoma: results of a phase II trial of rituximab.J Clin Oncol. 1999;17:1851\u20131857.","journal-title":"J Clin Oncol."},{"key":"BF02982803_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"P Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N, et al. Rituximab (anti CD-20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.Blood. 2001;97:101\u2013106.","journal-title":"Blood"},{"key":"BF02982803_CR23","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","volume":"95","author":"JD Hainsworth","year":"2000","unstructured":"Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin\u2019s lymphoma.Blood. 2000;95:3052\u20133056.","journal-title":"Blood"},{"key":"BF02982803_CR24","first-page":"294","volume":"20","author":"JD Hainsworth","year":"2001","unstructured":"Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab as first line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma [abstract].Proc Am Soc Clin Oncol. 2001;20: 294a. Abstract 1175.","journal-title":"Proc Am Soc Clin Oncol."},{"key":"BF02982803_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","volume":"17","author":"MS Czuczman","year":"1999","unstructured":"Czuczman MS, Grillo-L\u00f3pez AJ, White CA, et al. Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD-20 monoclonal antibody and CHOP chemotherapy.J Clin Oncol. 1999;17:268\u2013276.","journal-title":"J Clin Oncol."},{"key":"BF02982803_CR26","first-page":"601","volume":"98","author":"MS Czuczman","year":"2001","unstructured":"Czuczman MS, Grillo-L\u00f3pez AJ, White CA, et al. Progression free survival after six years (median) follow-up of the first clinical trial of rituximab\/CHOP chemoimmunotherapy [abstract].Blood. 2001;98:601a. Abstract 2519.","journal-title":"Blood"},{"key":"BF02982803_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","volume":"19","author":"JM Vose","year":"2001","unstructured":"Vose JM, Link BK, Grossboard ML, et al. Phase II Study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma.J Clin Oncol. 2001;19:389\u2013397.","journal-title":"J Clin Oncol."},{"key":"BF02982803_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e9re J, et al. CHOP chemotherapy plus rit-uximab compared with chop alone in elderly patients with diffuse large B-cell lymphoma.N Engl J Med. 2002;346:235\u2013242.","journal-title":"N Engl J Med."},{"key":"BF02982803_CR29","first-page":"601a","volume":"98","author":"MS Czuczman","year":"2001","unstructured":"Czuczman MS, Fallon A, Mohr A, et al. Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: final report [abstract].Blood. 2001;98:601a. Abstract 2518.","journal-title":"Blood"},{"key":"BF02982803_CR30","first-page":"601a","volume":"98","author":"M Herold","year":"2001","unstructured":"Herold M, Fielder F, Pasold R, et al. Efficacy and toxicity of rituximab plus mitoxantrone, chlorambucil, and prednisone (MCP) versus MCP alone in advanced indolent NHL- interim results of a clinical phase III study of the East German Study Group Hematology\/Oncology [abstract].Blood. 2001;98:601a. Abstract 2521.","journal-title":"Blood"},{"issue":"suppl 12","key":"BF02982803_CR31","first-page":"37","volume":"27","author":"P McLaughlin","year":"2000","unstructured":"McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.Semin Oncol. 2000;27(suppl 12):37\u201341.","journal-title":"Semin Oncol."},{"key":"BF02982803_CR32","first-page":"331a","volume":"96","author":"F Cabanillas","year":"2000","unstructured":"Cabanillas F, McLaughlin P, Hagemeister F, et al. Molecular responses with FND + Rituxan chemoimmunotherapy for stage IV indolent follicular non-Hodgkin\u2019s lymphoma [abstract].Blood. 2000;96:331a. Abstract 1429.","journal-title":"Blood"},{"key":"BF02982803_CR33","doi-asserted-by":"publisher","first-page":"343a","DOI":"10.1182\/blood.V98.2.343","volume":"98","author":"WH Wilson","year":"2001","unstructured":"Wilson WH, Pittaluga S, O\u2019Connor P, et al. Rituximab may overcome BCL-2 associated chemotherapy resistance in untreated diffuse large B-cell lymphomas [abstract].Blood. 2001;98:343a. Abstract 1447.","journal-title":"Blood"},{"key":"BF02982803_CR34","first-page":"290a","volume":"20","author":"WH Wilson","year":"2001","unstructured":"Wilson WH, Frankel SR, Drbohlav N, et al. Phase II study of dose- adjusted EPOCH-rituximab in untreated high risk large B-cell lymphomas [abstract].Proc Am Soc Clin Oncol. 2001;20:290a. Abstract 1158.","journal-title":"Proc Am Soc Clin Oncol."},{"key":"BF02982803_CR35","first-page":"290a","volume":"20","author":"LM Jost","year":"2001","unstructured":"Jost LM, Jermann M, Stahel RA, et al. Rituximab-EPOCH\u2014an effective salvage regime for relapsed, refractory, or transformed B-cell lymphoma: results of a phase II study [abstract].Proc Am Soc Clin Oncol. 2001;20:290a. Abstract 1157.","journal-title":"Proc Am Soc Clin Oncol."},{"key":"BF02982803_CR36","first-page":"346a","volume":"98","author":"T Kewalramani","year":"2001","unstructured":"Kewalramani T, Zelenetz A, Bertino J, et al. Rituximab significantly increases the complete response rate in patients with relapsed or primary DLBCL receiving ICE as second-line therapy (SLT) [abstract].Blood. 2001;98:346a. Abstract 1459.","journal-title":"Blood"},{"key":"BF02982803_CR37","first-page":"345a","volume":"98","author":"A Younes","year":"2001","unstructured":"Younes A, McLaughlin P, Hagemeister FB, et al. High response rate and complete remission rate achieved by adding rituximab to Taxol plus topotecan (TTR) with G-CSF support for the treatment of patients with relapsed\/refractory aggressive B-cell lymphoma [abstract].Blood. 2001;98:345a. Abstract 1456.","journal-title":"Blood"},{"key":"BF02982803_CR38","first-page":"2644","volume":"6","author":"TA Davis","year":"2000","unstructured":"Davis TA, Maloney DG, Grillo-L\u00f3pez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma with rituximab and interferon-\u03b1-2a.Clin Cancer Res. 2000;6:2644\u20132652.","journal-title":"Clin Cancer Res."},{"key":"BF02982803_CR39","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1200\/JCO.1998.16.10.3257","volume":"16","author":"J Lundin","year":"1998","unstructured":"Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin\u2019s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin\u2019s Lymphoma.J Clin Oncol. 1998;16:3257\u20133263.","journal-title":"J Clin Oncol."},{"key":"BF02982803_CR40","first-page":"284a","volume":"20","author":"BK Link","year":"2001","unstructured":"Link BK, Wang H, Byrd JC, et al. Phase I study of HuD10 monoclonal antibody (Remitogen) in patients with B-cell lymphoma [abstract].Proc Am Soc Clin Oncol. 2001;20:284a. Abstract 1135.","journal-title":"Proc Am Soc Clin Oncol."},{"key":"BF02982803_CR41","unstructured":"Link BK, Wang H, Byrd JC, et al. Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-HLA-DR monoclonal antibody Remitogen (Hu1D10) [abstract].Blood. 2001;98. Abstract 4703."},{"key":"BF02982803_CR42","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1182\/blood.V98.12.3178","volume":"98","author":"BK Link","year":"2001","unstructured":"Link BK, Kahl B, Czuczman M, et al. A phase II study of Remitogen (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone\/MALT B-cell lymphoma [abstract].Blood. 2001;98. Abstract 2450.","journal-title":"Blood"},{"issue":"suppl 1","key":"BF02982803_CR43","first-page":"92a","volume":"94","author":"JP Leonard","year":"1999","unstructured":"Leonard JP, Coleman M, Schuster MW, et al. Epratuzumab, a new anti-CD22-humanized monoclonal antibody for the therapy of non-Hodgkin\u2019s lymphoma (NHL): phase I\/II trials results [abstract].Blood. 1999;94(suppl 1):92a. Abstract 404.","journal-title":"Blood"},{"key":"BF02982803_CR44","first-page":"578a","volume":"96","author":"JP Leonard","year":"2000","unstructured":"Leonard JP, Coleman M, Chadburn A, et al. Epratuzumab (HLL2, anti-CD22 humanized monoclonal antibody) is an active and well-tolerated therapy for refractory\/relapsed diffuse large B-cell non-Hodgkin\u2019s lymphoma [abstract].Blood.2000;96:578a.Abstract 2482.","journal-title":"Blood"},{"key":"BF02982803_CR45","first-page":"1060","volume":"20","author":"JP Leonard","year":"2001","unstructured":"Leonard JP, Coleman M, Matthews JC, et al. Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin\u2019s lymphoma: preliminary response data.Proc Am Soc Clin Oncol. 2001;20. Abstract 1060.","journal-title":"Proc Am Soc Clin Oncol."},{"key":"BF02982803_CR46","doi-asserted-by":"crossref","unstructured":"Grillo-L\u00f3pez AJ, ed. Monoclonal antibodies in the treatment of hematologic malignancies.Curr Pharm Biotechnol. 2001;2(theme issue).","DOI":"10.2174\/1389201013378572"},{"key":"BF02982803_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/1389201013378635","volume":"2","author":"RJ Kreitman","year":"2001","unstructured":"Kreitman RJ. Toxin labeled monoclonal antibodies.Curr Pharm Biotechnol. 2001;2:313\u2013325.","journal-title":"Curr Pharm Biotechnol."},{"key":"BF02982803_CR48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2174\/1389201013378590","volume":"2","author":"RF Meredith","year":"2001","unstructured":"Meredith RF, Knox SJ. Radioimmunotherapy of B-Cell NHL.Curr Pharm Biotechnol. 2001;2:327\u2013339.","journal-title":"Curr Pharm Biotechnol."},{"key":"BF02982803_CR49","first-page":"2560","volume":"96","author":"G Hajjar","year":"2000","unstructured":"Hajjar G, Sharkey RM, Burton J, et al. Interim results of a phase I\/ II radioimmunotherapy trial in relapsed\/refractory non-Hodgkin\u2019s lymphoma patients given90yttrium labeled anti-CD22 humanized monoclonal antibody, epratuzumab [abstract].Blood. 2000;96. Abstract 2560.","journal-title":"Blood"},{"key":"BF02982803_CR50","first-page":"3147","volume":"40","author":"LM Nadler","year":"1980","unstructured":"Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.Cancer Res. 1980;40:3147\u20133154.","journal-title":"Cancer Res."},{"key":"BF02982803_CR51","unstructured":"Gockerman J, Gregory S, Harwood S, et al. Interim efficacy results of Bexxar in a large multicenter open access study [abstract].J Clin Oncol. 2001. Abstract 1138."},{"key":"BF02982803_CR52","first-page":"287a","volume":"20","author":"L Fehrenbacher","year":"2001","unstructured":"Fehrenbacher L, Radford J, Kaminski M, et al. Patient-specific dosing of Bexxar is associated with tolerable and predictable hematologic toxicity in patients with known hematologic risk factors [abstract].J Clin Oncol. 2001;20:287a. Abstract 1144.","journal-title":"J Clin Oncol."},{"key":"BF02982803_CR53","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","volume":"19","author":"MS Kaminsky","year":"2001","unstructured":"Kaminsky MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I131 tositumomab for chemotherapy refractory low grade or transformed low grade B-cell non-Hodgkin\u2019s lymphoma.J Clin Oncol. 2001;19:3918\u20133928.","journal-title":"J Clin Oncol."},{"key":"BF02982803_CR54","first-page":"65","volume":"86","author":"AJ Grillo-L\u00f3pez","year":"2001","unstructured":"Grillo-L\u00f3pez AJ. Radioimmunotherapy with 90-yttrium Zevalin for indolent or aggressive non-Hodgkin\u2019s lymphomas.Haemato-logica. 2001;86:65\u201369.","journal-title":"Haemato-logica"},{"key":"BF02982803_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1389201003379059","volume":"1","author":"AJ,White CA Grillo-L\u00f3pez","year":"2000","unstructured":"Grillo-L\u00f3pez AJ,White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.Curr Pharm Biotechnol. 2000;1:1\u20139.","journal-title":"Curr Pharm Biotechnol."},{"issue":"suppl 2","key":"BF02982803_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/sonc.2002.30145","volume":"29","author":"AJ Grillo-L\u00f3pez","year":"2002","unstructured":"Grillo-L\u00f3pez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development.Semin Oncol. 2002; 29(suppl 2):105\u2013112.","journal-title":"Semin Oncol."},{"key":"BF02982803_CR57","unstructured":"Grillo-L\u00f3pez AJ. Curative therapies for NHL: a question of time! [editorial].Curr Pharm Biotechnol. 2001;2(theme issue)."},{"key":"BF02982803_CR58","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"R Fisher","year":"1993","unstructured":"Fisher R, Gaynor E, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma.N Engl J Med. 1993;328: 1002\u20131006.","journal-title":"N Engl J Med."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF02982803\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982803.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982803.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T23:45:02Z","timestamp":1659051902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF02982803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["BF02982803"],"URL":"https:\/\/doi.org\/10.1007\/bf02982803","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]},"assertion":[{"value":"11 July 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}